Merck & Co., Inc. (NYSE:MRK) Shares Bought by BerganKDV Wealth Management LLC

BerganKDV Wealth Management LLC grew its position in Merck & Co., Inc. (NYSE:MRK) by 2.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,822 shares of the company’s stock after purchasing an additional 660 shares during the period. BerganKDV Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $2,086,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Resources Investment Advisors LLC. increased its holdings in shares of Merck & Co., Inc. by 9.1% in the second quarter. Resources Investment Advisors LLC. now owns 35,473 shares of the company’s stock valued at $2,759,000 after purchasing an additional 2,971 shares during the period. Sigma Planning Corp increased its holdings in shares of Merck & Co., Inc. by 15.3% in the first quarter. Sigma Planning Corp now owns 73,515 shares of the company’s stock valued at $5,667,000 after purchasing an additional 9,762 shares during the period. Davidson Capital Management Inc. increased its holdings in shares of Merck & Co., Inc. by 13.9% in the second quarter. Davidson Capital Management Inc. now owns 15,982 shares of the company’s stock valued at $1,243,000 after purchasing an additional 1,956 shares during the period. Brandywine Oak Private Wealth LLC increased its holdings in shares of Merck & Co., Inc. by 57.7% in the second quarter. Brandywine Oak Private Wealth LLC now owns 29,581 shares of the company’s stock valued at $2,300,000 after purchasing an additional 10,829 shares during the period. Finally, Naples Global Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 4.6% in the first quarter. Naples Global Advisors LLC now owns 81,214 shares of the company’s stock valued at $6,261,000 after purchasing an additional 3,578 shares during the period. 71.83% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have recently weighed in on the company. Truist Securities assumed coverage on Merck & Co., Inc. in a report on Tuesday, July 27th. They issued a “buy” rating and a $76.79 price objective on the stock. Truist assumed coverage on Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $92.00 target price on the stock. Morgan Stanley downgraded Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $90.00 to $85.00 in a research note on Tuesday, September 7th. Zacks Investment Research upgraded Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 target price on the stock in a research note on Tuesday, August 24th. Finally, JPMorgan Chase & Co. lowered their target price on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 9th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $91.09.

MRK stock traded up $0.77 during mid-day trading on Wednesday, reaching $72.88. 481,449 shares of the company’s stock were exchanged, compared to its average volume of 11,229,302. The company has a market cap of $184.49 billion, a price-to-earnings ratio of 32.93, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. The stock’s 50 day moving average is $76.68 and its 200 day moving average is $76.59. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.31 and a quick ratio of 1.06. Merck & Co., Inc. has a 12-month low of $71.71 and a 12-month high of $86.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.31. The company had revenue of $11.40 billion for the quarter, compared to the consensus estimate of $11.21 billion. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. During the same quarter in the prior year, the business posted $1.37 earnings per share. On average, research analysts forecast that Merck & Co., Inc. will post 5.51 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 7th. Stockholders of record on Wednesday, September 15th will be given a $0.65 dividend. The ex-dividend date is Tuesday, September 14th. This represents a $2.60 annualized dividend and a dividend yield of 3.57%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 43.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Story: Stock Portfolio Tracker

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.